Affimer News and Research

RSS
How Can CPNs Revolutionize Medical Diagnostics?

How Can CPNs Revolutionize Medical Diagnostics?

Scientists uncover new way to target a mutant protein that causes the deadliest of cancers

Scientists uncover new way to target a mutant protein that causes the deadliest of cancers

Avacta Group announces significant progress in the development of SARS-CoV-2 rapid antigen test

Avacta Group announces significant progress in the development of SARS-CoV-2 rapid antigen test

Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection

Avacta to launch Affimer-based ELISA test for SARS-CoV-2 virus detection

Avacta enters into manufacturing agreement with Abingdon Health for rapid SARS-CoV-2 antigen test

Avacta enters into manufacturing agreement with Abingdon Health for rapid SARS-CoV-2 antigen test

Avacta expands multi-target collaboration with LG Chem Life Sciences

Avacta expands multi-target collaboration with LG Chem Life Sciences

Neil Bell appointed as Chief Development Officer of Avacta Life Sciences

Neil Bell appointed as Chief Development Officer of Avacta Life Sciences

Avacta appoints COVID-19 rapid antigen test manufacturing partner

Avacta appoints COVID-19 rapid antigen test manufacturing partner

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy

Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy

Avacta provides update on clinical validation of Adeptrix COVID-19 diagnostic test

Avacta provides update on clinical validation of Adeptrix COVID-19 diagnostic test

Avacta provides update on clinical validation of Adeptrix COVID-19 diagnostic test

Avacta provides update on clinical validation of Adeptrix COVID-19 diagnostic test

Avacta and Integumen team up for detection of novel coronavirus in waste water

Avacta and Integumen team up for detection of novel coronavirus in waste water

Avacta provides update on COVID-19 rapid antigen test development partnership with Cytiva

Avacta provides update on COVID-19 rapid antigen test development partnership with Cytiva

Avacta provides update on Affimer therapy for COVID-19 infection

Avacta provides update on Affimer therapy for COVID-19 infection

Avacta provides update on COVID-19 antigen diagnostic test development with Adeptrix

Avacta provides update on COVID-19 antigen diagnostic test development with Adeptrix

Avacta and Medusa19 enter into a distribution agreement for COVID-19 antigen test

Avacta and Medusa19 enter into a distribution agreement for COVID-19 antigen test

Avacta's SARS-COV-2 neutralizing Affimer reagents show therapeutic potential for COVID-19

Avacta's SARS-COV-2 neutralizing Affimer reagents show therapeutic potential for COVID-19

Developing a COVID-19 antigen test

Developing a COVID-19 antigen test

Avacta Group plc forms COVID-19 antigen diagnostic collaboration with Adeptrix

Avacta Group plc forms COVID-19 antigen diagnostic collaboration with Adeptrix

Avacta successfully generates several highly specific Affimer reagents for COVID-19 antigen rapid test ahead of schedule as part of Cytiva partnership

Avacta successfully generates several highly specific Affimer reagents for COVID-19 antigen rapid test ahead of schedule as part of Cytiva partnership

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.